Remix Therapeutics

Reprogramming RNA to transform patients’ lives.

Learn More

Current Beat

Apr | 15 | 2025
Press Release
Remix Therapeutics™ Appoints Linda C. Bain to Board of Directors
Watertown, Mass. (April 15, 2025) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of life science executive, Linda C. Bain, to its Board of Directors. Ms. Bain is a Venture Partner at Atlas Venture and currently […]
Read More
Mar | 31 | 2025
Press Release
Remix Therapeutics™ to Present at Stifel 2025 Virtual Targeted Oncology Forum
Watertown, Mass. (March 31, 2025) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Stifel 2025 Virtual Targeted Oncology Forum on […]
Read More
Nov | 26 | 2024
Press Release
Remix Therapeutics™ to Present at 7th Annual Evercore HealthCONx Conference
Cambridge, Mass. (November 26, 2024) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the 7th Annual Evercore HealthCONx Conference in Miami […]
Read More
Nov | 20 | 2024
Press Release
Remix Therapeutics™ to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)
REM-422, a First-in-Class Small Molecule MYB mRNA Degrader, Demonstrates Anti-Leukemic Activity as Monotherapy and in Combination in Preclinical Models of AML WATERTOWN, Mass., November 20, 2024 – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced an upcoming oral presentation […]
Read More

REMaster™ Drug
Discovery Platform

Our proprietary platform designs small molecules that harness cellular machineries to control RNA processing and modulate expression of disease drivers.
Learn More
Data Science
Identifying druggable high value targets
Biology &
Biomolecular Sciences
Functional target validation and multiplexed HTS assays
Medicinal &
Computational Chemistry
Compound identification and optimization from proprietary library

It's Sound Science

About Us
Remix™ launched in 2020 with a vision to transform patient's lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. We take on the challenge of addressing drug targets in diseases of high unmet medical need to bring new therapeutic options to patients. Remix has a commitment to demonstrate the highest levels of scientific integrity with urgency because those patients are counting on us to deliver. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.
About Us
Join Us

Become a Remixer

Remix™ welcomes new people and perspectives to join us in pushing scientific boundaries to offer new hope to patients.
Join the Team

Contact

General Inquiry